The standard story of drug development goes like this: a researcher identifies a promising molecule, spends years characterizing its biology, runs it through Phase 1 safety trials, Phase 2 efficacy trials, and Phase 3 confirmatory trials, submits a mountain of data to the FDA, and — a decade and a billion dollars later — brings a new medicine to patients.

This is how it usually works. It is slow, expensive, and failure-prone. Roughly 90% of drugs that enter clinical trials never make it to approval. The ones that do typically require $1–2 billion in investment and ten to fifteen years of development time.

For diseases where there are zero approved treatments — and where the patients who need them are suffering right now — that timeline is not just a business problem. It is an ethical one.

Drug repurposing is one serious answer to that problem. It is also, increasingly, the strategy behind some of the most impactful treatments in medicine.

What repurposing actually means

Drug repurposing — also called drug repositioning — is the practice of applying an existing, approved medicine to a new indication that wasn't part of its original development.

The logic is straightforward. A drug that has already cleared clinical trials and reached approval has already done the hardest thing a pharmaceutical compound has to do: it has demonstrated that it is safe in humans. Its metabolism, its side effect profile, its tolerability in different populations — all of that data already exists. The development risk that kills 90% of new molecules has, to a meaningful degree, already been resolved.

What remains to be demonstrated is efficacy in the new indication.

That is still a real and significant scientific question. But it is a fundamentally different and smaller question than asking whether a completely new molecule is both safe and effective. The FDA recognizes this distinction explicitly — which is why it has created a regulatory pathway designed specifically for repurposed drugs.

The 505(b)(2) pathway: what it is and why it matters

The FDA's standard approval pathway for a new drug is called the 505(b)(1). It requires a complete, independent package of safety and efficacy data from scratch.

The 505(b)(2) pathway allows a developer to rely — with appropriate credit — on safety data that already exists in the published literature or in prior FDA approvals. If a drug has already demonstrated acceptable safety in humans under an approved indication, a developer pursuing a new use doesn't need to repeat all of that safety work from the beginning. They can reference what's already known and focus their clinical program on demonstrating efficacy in the new population.

The practical implications are significant:

  • Timeline. A 505(b)(2) development program can potentially move from pre-clinical studies to Phase 2 trials in three to four years rather than eight to ten. The safety stage — historically one of the longest and most expensive — is compressed by the existing safety record.
  • Capital. The Phase 1 safety trials that typically consume tens of millions of dollars can be substantially reduced or, in some cases, skipped. This changes the capital profile of the program materially.
  • Risk. The biggest uncertainty in early drug development is usually safety, not efficacy. Starting with a known safety profile shifts the risk distribution. You are still taking an efficacy bet, but you are not also taking a safety bet from zero.

For investors, this is the difference between a program that needs $500 million and fifteen years to reach approval and one that may need significantly less of both. For patients, it is the difference between a potential treatment in their lifetime and one that arrives — if it arrives — too late.

The track record

Drug repurposing is not a novel concept or a boutique strategy. Some of the most important medicines in use today were discovered this way.

Aspirin, originally developed as a pain reliever and anti-inflammatory, is now a cornerstone of cardiovascular disease prevention. Thalidomide, withdrawn in the 1960s due to devastating teratogenic effects in pregnancy, was repurposed with strict controls to treat multiple myeloma and leprosy. Metformin, developed decades ago as a diabetes drug, is now one of the most heavily studied compounds in aging and cancer prevention research. Sildenafil, which failed as a cardiovascular drug, became the treatment for pulmonary arterial hypertension — and, under a different name, for erectile dysfunction.

More recently, during the COVID-19 pandemic, the urgency of finding treatments drove a massive acceleration in repurposing research. Dexamethasone — a corticosteroid in clinical use since the 1960s — became one of the most important tools in managing severe COVID-19. It worked precisely because its safety profile was completely understood: there was no need to test whether it was safe to give to critically ill patients.

The pattern across all of these examples is the same: a drug with an established safety record, applied with intelligence to a new indication, gets to patients faster and more cheaply than a drug developed from scratch.

NS-001: the specific case

Nulyn Science's lead asset, NS-001, follows this logic directly.

NS-001 is a small organic molecule that has been globally approved for an unrelated indication for many years. Its safety profile — including extensive data in elderly patients and medically complex populations — is well-characterized in the literature and in its original regulatory record. The team at Nulyn includes one of the scientists who led its original development, which means the institutional knowledge about this compound is not being reconstructed from scratch.

What is new is the discovery of what NS-001 does in the brain.

NS-001 is a potent, brain-penetrant inhibitor of the inflammatory cytokines — particularly TNF-α — that drive the neuroinflammatory cascades underlying postoperative cognitive dysfunction (POCD) and chemotherapy-induced cognitive impairment (CICI). In preclinical studies, a single dose administered around the time of the triggering event — surgery or chemotherapy — significantly reduced microglial activation and preserved cognitive performance in animal models of both conditions.

The fact that NS-001 crosses the blood-brain barrier is not incidental. Many anti-inflammatory drugs are effective in the periphery but cannot reach the brain in meaningful concentrations. NS-001's brain penetrance is what makes it a plausible candidate for conditions that are fundamentally neurological in their mechanism.

Because NS-001 is already approved, Nulyn is pursuing the 505(b)(2) pathway. This means our Phase 2 trial in POCD — currently scheduled to begin in the second half of 2026 in Brazil — is not preceded by a multi-year Phase 1 safety program. We are moving into efficacy trials in patients with a safety profile already in hand.

The honest limitations

Repurposing is not magic, and it would be misleading to suggest that the 505(b)(2) pathway eliminates development risk. It compresses and redistributes it; it doesn't remove it.

Efficacy in a new indication is not guaranteed by safety in an old one. The biology has to work. The mechanism has to be real. The dose, the timing, and the population all have to be right. These are the questions that Phase 2 and Phase 3 trials exist to answer, and they are real questions with uncertain outcomes.

The intellectual honesty required in drug repurposing is also non-trivial. The temptation, when a molecule has an established safety record and a plausible new mechanism, is to move faster than the science actually supports. The existing safety data removes some risk. It doesn't remove the obligation to do rigorous, well-controlled clinical trials in the new indication.

What repurposing does — done carefully — is make it possible to pursue that science in a timeline that is realistic for patients who are suffering from conditions with no current treatment options. That is the combination of circumstances that defines an unmet need, and that is the circumstance Nulyn was built for.

A different kind of innovation

There is sometimes a perception in the pharmaceutical industry that drug repurposing is somehow less innovative than discovering a new molecule — that working with an existing compound is a second-best strategy, reserved for developers who can't or won't do the harder work of true discovery.

This perception is wrong, and it is worth saying so directly.

The insight that a known compound has an undiscovered mechanism in a new context — that a drug approved for one reason works for an entirely different reason, in an entirely different part of the body — is a genuine scientific discovery. It requires understanding mechanisms deeply enough to see what others have missed. It requires access to the right preclinical models. And it requires the judgment to know when the evidence is strong enough to justify a clinical program.

The speed and capital efficiency that result are not a shortcut. They are the reward for having done the mechanistic science correctly.

For the patients waiting for a treatment for POCD and CICI, the distinction between "novel molecule" and "repurposed compound" is irrelevant. What matters is whether something works. The 505(b)(2) pathway, used properly, is how we intend to answer that question.